You are here: Home » International » News » Others
Business Standard

US says it won't join WHO's global effort to find coronavirus vaccine

The Trump administration that it will not work with an international cooperative effort to develop and distribute a COVID-19 vaccine

Topics
Coronavirus | Donald Trump administration | World Health Organisation

AP  |  Washington 

Photo: Shutterstock
Photo: Shutterstock

The Trump administration said Tuesday that it will not work with an cooperative effort to develop and distribute a COVID-19 vaccine because it does not want to be constrained by multilateral groups like the World Health Organization.

The decision to go it alone, first reported by The Washington Post, follows the White House's decision in early July to pull the United States out of the WHO. Trump claims the WHO is in need of reform and is heavily influenced by China.

Some nations have worked directly to secure supplies of vaccine, but are pooling efforts to ensure success against a disease that has no geographical boundaries.

More than 150 countries are setting up the COVID-19 Vaccines Global Access Facility, or COVAX.

That cooperative effort, linked with the WHO, would allow nations to take advantage of a portfolio of potential vaccines to ensure their citizens are quickly covered by whichever ones are deemed effective.

The WHO says even governments making deals with individual vaccine makers would benefit from joining COVAX because it would provide backup vaccines in case the ones being made through bilateral deals with manufacturers aren't successful.

The United States will continue to engage our partners to ensure we defeat this virus, but we will not be constrained by multilateral organizations influenced by the corrupt World Health Organization and China," said White House spokesman Judd Deere.

"This president will spare no expense to ensure that any new vaccine maintains our own Food and Drug Administration's gold standard for safety and efficacy, is thoroughly tested and saves lives.

Rep. Ami Bera, D-Calif., said the administration's decision was shortsighted and will hamper the battle to end the pandemic.

Joining COVAX is a simple measure to guarantee U.S. access to a vaccine no matter who develops it first, tweeted Bera, a medical doctor.

This go-it-alone approach leaves America at risk of not getting a vaccine.

The administration's decision, paired with the U.S. withdrawal from the WHO, means the U.S. is abdicating America's global leadership in fighting pandemics, according to Tom Hart, North America director at The ONE Campaign, an advocacy organization co-founded by Bono of the rock band U2.

"Not only does this move put the lives of millions around the world at risk, it could completely isolate Americans from an effective vaccine against COVID-19, Hart said.

A handful of the dozens of experimental COVID-19 vaccines in human testing have reached the last and biggest hurdle looking for the needed proof that they really work.

AstraZeneca announced Monday its vaccine candidate has entered the final testing stage in the U.S. The Cambridge, England-based company said the study will involve up to 30,000 adults from various racial, ethnic and geographic groups.

Two other vaccine candidates began final testing this summer in tens of thousands of people in the U.S. One was created by the National Institutes of Health and manufactured by Moderna Inc., and the other developed by Pfizer Inc. and Germany's BioNTech.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Wed, September 02 2020. 07:24 IST
RECOMMENDED FOR YOU
.